<DOC>
	<DOCNO>NCT03045120</DOCNO>
	<brief_summary>This non-interventional , prospective study characterize impact three approve first second generation BCR-ABL1 tyrosine kinase inhibitor cardiovascular metabolic risk factor chronic phase CML ( CP-CML ) patient TKI naive initiate first-line TKIs routine clinical practice US . All treatment decision determine discretion treat physician ( ) data identify cardiovascular metabolic risk factor collect . Additional fast blood sample ( collect follow 8 hour fast ) collect standard care ( SOC ) /routine office visit . Additional research imaging perform review core image laboratory . As study collect data management CML , study influence prescribe management practice participate site .</brief_summary>
	<brief_title>Determining Change Cardiovascular Metabolic Risks Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy United States</brief_title>
	<detailed_description>This non-interventional , prospective study characterize impact three approve first second generation BCR-ABL1 tyrosine kinase inhibitor cardiovascular metabolic risk factor chronic phase CML ( CP-CML ) patient TKI naive initiate first-line TKIs routine clinical practice US . All treatment decision determine discretion treat physician ( ) data identify cardiovascular metabolic risk factor collect . Additional fast blood sample ( collect follow 8 hour fast ) collect standard care ( SOC ) /routine office visit . Additional research imaging perform review core image laboratory . As study collect data management CML , study influence prescribe management practice participate site .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>1 . ≥ 18 year time Ph+ CPCML diagnosis 2 . Newly diagnose chronic phase Ph+ CPCML , confirm cytogenetic and/or molecular test baseline 3 . Treatmentnaïve initiate treatment dasatinib , imatinib , nilotinib 4 . Willingness ability comply routine office visit 1 . Any prior active nonCML active malignancy patient receive treatment 2 . Participation therapeutic clinical trial CML disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>